SciELO - Scientific Electronic Library Online

 
vol.28 issue4Glioblastoma multiforme cerebral hemisférico: análisis de sobrevida de 65 casos tratados en el Departamento de Oncología del Hospital de Clínicas, desde 1980 a 2000 author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista Médica del Uruguay

On-line version ISSN 1688-0390

Abstract

CASTILLO, Cecilia et al. Análisis de sobrevida según perfil biológico de pacientes uruguayas con cáncer de mama. Rev. Méd. Urug. [online]. 2012, vol.28, n.4, pp.241-249. ISSN 1688-0390.

Abstract Introduction: breast cancer constitutes an heterogeneous disease. Two sub-types have been distinguished through the study of the tumor expression level of hormone receptors tumors, and level of HER2 expression, among other techniques. We previously reported the relation between these sub-types and the clinical and pathological characteristics of Uruguayan women. Objective: to analyse the disease-free survival (DFS) of Uruguayan patients with breast cancer, according to their biological sub-type, defined based on the tumor expression of hormone receptors and HER2 expression which were assessed by immune-histological chemistry staining. Method: all clinical records of patients who had undergone breast cancer surgery (Stages I-III) during a two year period were reviewed. The disease-free survival rate was calculated for all patients and according to their biological profile. Results: forty months follow up revealed disease-free survival upon two years of 92.3% for all patients; 94% for hormone receptor positive /HER2 negative patients, 91% for triple negative patients, and 71.4% for hormone receptor positive patients. Comparing the DFS curves, for the different sub-types, evidenced a lower DFS for HER2+ patients (p = 0.03), and similar DFS for hormone receptor positive/HER2 negative and triple negative (p = 0.86). Conclusions: uruguayan patients with breast cancer show a two-year-DFS that matches international reports. HER2+ patients evidence a higher relapse rate, also consistent with international reports. Similar DFS upon two years, between hormone receptor positive/HER2 negative patients and triple negative patients cannot be due to differences in the clinical-pathological characteristics, thus a hypothesis is considered: there is a larger proportion of patients of the luminal B breast cancer sub-type among hormone receptor positive/HER2 negative patients.

Keywords : SURVIVAL ANALYSIS; PROGNOSIS; BREAST NEOPLASMS; RECEPTORS, STROGEN; RECEPTORS, PROGESTERONE; RECEPTOR, erbB-2.

        · abstract in Spanish | Portuguese     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License